165 related articles for article (PubMed ID: 38293803)
1. Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study.
Glue P; Neehoff S; Beaglehole B; Shadli S; McNaughton N; Hughes-Medlicott NJ
J Psychopharmacol; 2024 Feb; 38(2):162-167. PubMed ID: 38293803
[TBL] [Abstract][Full Text] [Related]
2. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Glue P; Medlicott NJ; Harland S; Neehoff S; Anderson-Fahey B; Le Nedelec M; Gray A; McNaughton N
J Psychopharmacol; 2017 Oct; 31(10):1302-1305. PubMed ID: 28441895
[TBL] [Abstract][Full Text] [Related]
3. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
[No Abstract] [Full Text] [Related]
4. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
6. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of intranasal ketamine in major depressive disorder.
Lapidus KA; Levitch CF; Perez AM; Brallier JW; Parides MK; Soleimani L; Feder A; Iosifescu DV; Charney DS; Murrough JW
Biol Psychiatry; 2014 Dec; 76(12):970-6. PubMed ID: 24821196
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M; Freeman MP; Flynn M; Judge H; Hoeppner BB; Cusin C; Ionescu DF; Mathew SJ; Chang LC; Iosifescu DV; Murrough J; Debattista C; Schatzberg AF; Trivedi MH; Jha MK; Sanacora G; Wilkinson ST; Papakostas GI
Mol Psychiatry; 2020 Jul; 25(7):1592-1603. PubMed ID: 30283029
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
Chen MH; Cheng CM; Gueorguieva R; Lin WC; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Krystal JH; Su TP
Neuropsychopharmacology; 2019 Nov; 44(12):2112-2118. PubMed ID: 31421635
[TBL] [Abstract][Full Text] [Related]
13. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.
Swainson J; McGirr A; Blier P; Brietzke E; Richard-Devantoy S; Ravindran N; Blier J; Beaulieu S; Frey BN; Kennedy SH; McIntyre RS; Milev RV; Parikh SV; Schaffer A; Taylor VH; Tourjman V; van Ameringen M; Yatham LN; Ravindran AV; Lam RW
Can J Psychiatry; 2021 Feb; 66(2):113-125. PubMed ID: 33174760
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
[TBL] [Abstract][Full Text] [Related]
15. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
[TBL] [Abstract][Full Text] [Related]
16. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
17. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
[TBL] [Abstract][Full Text] [Related]
19. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Singh JB; Fedgchin M; Daly EJ; De Boer P; Cooper K; Lim P; Pinter C; Murrough JW; Sanacora G; Shelton RC; Kurian B; Winokur A; Fava M; Manji H; Drevets WC; Van Nueten L
Am J Psychiatry; 2016 Aug; 173(8):816-26. PubMed ID: 27056608
[TBL] [Abstract][Full Text] [Related]
20. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
